MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
68.05
+4.32
+6.78%
After Hours: 69.40 +1.35 +1.98% 19:40 02/06 EST
OPEN
70.08
PREV CLOSE
63.73
HIGH
70.63
LOW
67.59
VOLUME
4.74M
TURNOVER
--
52 WEEK HIGH
81.33
52 WEEK LOW
28.33
MARKET CAP
13.11B
P/E (TTM)
-16.2535
1D
5D
1M
3M
1Y
5Y
1D
BridgeBio Pharma (BBIO) Gets a Buy from Evercore ISI
TipRanks · 1d ago
BridgeBio Pharma (BBIO) Receives a Buy from Bernstein
TipRanks · 1d ago
BridgeBio Pharma (BBIO) Receives a Buy from Cantor Fitzgerald
TipRanks · 1d ago
Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)
TipRanks · 1d ago
BridgeBio Pharma (BBIO) Receives a Buy from Barclays
TipRanks · 1d ago
Bank of America Securities Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Demant (OtherWILLF) and Tenet Healthcare (THC)
TipRanks · 4d ago
BridgeBio price target raised to $88 from $85 at BofA
TipRanks · 4d ago
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.